# Rallybio Corp: financial statements, quarterly

RLYB · Nasdaq · CIK 1739410 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rlyb.md) · [Financials](/companies/rlyb/financials.md) · [Filings](/companies/rlyb/filings.md) · [Insiders](/companies/rlyb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rlyb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.0](/filings/0001739410-25-000061.md) | [0.3](/filings/0001739410-25-000112.md) | [0.3](/filings/0001739410-25-000132.md) | [0.0 d](/filings/0001628280-26-018261.md) | [0.2](/filings/0001628280-26-034580.md) | [0.2](/filings/0001628280-26-053880.md) | [0.2](/filings/0001628280-26-067422.md) | [0.2 d](/filings/0001628280-26-018261.md) | [0.2](/filings/0001628280-26-034580.md) | [0.0](/filings/0001628280-26-053880.md) | [0.0](/filings/0001628280-26-067422.md) |
| Research and development | $m | [15.9 d](/filings/0001739410-25-000040.md) | [12.9](/filings/0001739410-25-000061.md) | [12.9](/filings/0001739410-25-000112.md) | [8.2](/filings/0001739410-25-000132.md) | [7.4 d](/filings/0001628280-26-018261.md) | [5.7](/filings/0001628280-26-034580.md) | [6.1](/filings/0001628280-26-053880.md) | [4.1](/filings/0001628280-26-067422.md) | [3.7 d](/filings/0001628280-26-018261.md) | [2.9](/filings/0001628280-26-034580.md) | [0.8](/filings/0001628280-26-053880.md) | [0.6](/filings/0001628280-26-067422.md) |
| Operating income | $m | [(21.1) d](/filings/0001739410-25-000040.md) | [(19.8)](/filings/0001739410-25-000061.md) | [(17.0)](/filings/0001739410-25-000112.md) | [(12.1)](/filings/0001739410-25-000132.md) | [(11.6) d](/filings/0001628280-26-018261.md) | [(9.7)](/filings/0001628280-26-034580.md) | [(10.1)](/filings/0001628280-26-053880.md) | [(6.9)](/filings/0001628280-26-067422.md) | [(6.4) d](/filings/0001628280-26-018261.md) | [(8.7)](/filings/0001628280-26-034580.md) | [(5.7)](/filings/0001628280-26-053880.md) | [(3.4)](/filings/0001628280-26-067422.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001628280-26-053880.md) | [0.0](/filings/0001628280-26-067422.md) | [0.0 d](/filings/0001628280-26-018261.md) | not reported | [1.3](/filings/0001628280-26-053880.md) | [0.1](/filings/0001628280-26-067422.md) |
| Net income | $m | [(20.2) d](/filings/0001739410-25-000040.md) | [(19.0)](/filings/0001739410-25-000061.md) | [(16.2)](/filings/0001739410-25-000112.md) | [(11.5)](/filings/0001739410-25-000132.md) | [(11.0) d](/filings/0001628280-26-018261.md) | [(9.4)](/filings/0001628280-26-034580.md) | [(9.7)](/filings/0001628280-26-053880.md) | [16.0](/filings/0001628280-26-067422.md) | [(5.9) d](/filings/0001628280-26-018261.md) | [(8.3)](/filings/0001628280-26-034580.md) | [43.7](/filings/0001628280-26-053880.md) | [(2.7)](/filings/0001628280-26-067422.md) |
| Diluted EPS | $ per share | not reported | [(0.47)](/filings/0001739410-25-000061.md) | [(0.37)](/filings/0001739410-25-000112.md) | [(0.26)](/filings/0001739410-25-000132.md) | not reported | [(1.69)](/filings/0001628280-26-034580.md) | [(0.22)](/filings/0001739410-25-000112.md) | [2.84](/filings/0001628280-26-067422.md) | not reported | [(1.46)](/filings/0001628280-26-034580.md) | [7.53](/filings/0001628280-26-053880.md) | [(0.48)](/filings/0001628280-26-067422.md) |
| Basic EPS | $ per share | not reported | [(0.47)](/filings/0001739410-25-000061.md) | [(0.37)](/filings/0001739410-25-000112.md) | [(0.26)](/filings/0001739410-25-000132.md) | not reported | [(1.69)](/filings/0001628280-26-034580.md) | [(1.73)](/filings/0001628280-26-053880.md) | [2.84](/filings/0001628280-26-067422.md) | not reported | [(1.46)](/filings/0001628280-26-034580.md) | [7.66](/filings/0001628280-26-053880.md) | [(0.48)](/filings/0001628280-26-067422.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.5](/filings/0001739410-25-000040.md) | [19.3](/filings/0001739410-24-000057.md) | [16.7](/filings/0001739410-24-000115.md) | [25.3](/filings/0001739410-24-000136.md) | [13.9](/filings/0001628280-26-018261.md) | [14.8](/filings/0001739410-25-000061.md) | [9.4](/filings/0001739410-25-000112.md) | [32.1](/filings/0001739410-25-000132.md) | [31.4](/filings/0001628280-26-067422.md) | [41.3](/filings/0001628280-26-034580.md) | [92.8](/filings/0001628280-26-053880.md) | [90.7](/filings/0001628280-26-067422.md) |
| Current assets | $m | [115](/filings/0001739410-25-000040.md) | [98.5](/filings/0001739410-24-000057.md) | [91.4](/filings/0001739410-24-000115.md) | [78.2](/filings/0001739410-24-000136.md) | [67.8](/filings/0001628280-26-018261.md) | [57.4](/filings/0001739410-25-000061.md) | [50.3](/filings/0001739410-25-000112.md) | [66.6](/filings/0001739410-25-000132.md) | [61.3](/filings/0001628280-26-067422.md) | [53.5](/filings/0001628280-26-034580.md) | [97.3](/filings/0001628280-26-053880.md) | [94.8](/filings/0001628280-26-067422.md) |
| Total assets | $m | [116](/filings/0001739410-25-000040.md) | [99.4](/filings/0001739410-24-000057.md) | [92.4](/filings/0001739410-24-000115.md) | [79.0](/filings/0001739410-24-000136.md) | [68.1](/filings/0001628280-26-018261.md) | [58.0](/filings/0001739410-25-000061.md) | [51.0](/filings/0001739410-25-000112.md) | [67.7](/filings/0001739410-25-000132.md) | [62.3](/filings/0001628280-26-067422.md) | [54.5](/filings/0001628280-26-034580.md) | [98.1](/filings/0001628280-26-053880.md) | [95.6](/filings/0001628280-26-067422.md) |
| Current liabilities | $m | [9.3](/filings/0001739410-25-000040.md) | [10.1](/filings/0001739410-24-000057.md) | [12.2](/filings/0001739410-24-000115.md) | [8.2](/filings/0001739410-24-000136.md) | [6.2](/filings/0001628280-26-018261.md) | [3.9](/filings/0001739410-25-000061.md) | [5.0](/filings/0001739410-25-000112.md) | [4.5](/filings/0001739410-25-000132.md) | [4.2](/filings/0001628280-26-067422.md) | [4.1](/filings/0001628280-26-034580.md) | [3.6](/filings/0001628280-26-053880.md) | [3.3](/filings/0001628280-26-067422.md) |
| Total liabilities | $m | [9.4](/filings/0001739410-25-000040.md) | [10.2](/filings/0001739410-24-000057.md) | [12.4](/filings/0001739410-24-000115.md) | [8.2](/filings/0001739410-24-000136.md) | [6.5](/filings/0001628280-26-018261.md) | [3.9](/filings/0001739410-25-000061.md) | [5.0](/filings/0001739410-25-000112.md) | [4.6](/filings/0001739410-25-000132.md) | [4.3](/filings/0001628280-26-067422.md) | [4.2](/filings/0001628280-26-034580.md) | [3.6](/filings/0001628280-26-053880.md) | [3.3](/filings/0001628280-26-067422.md) |
| Shareholders' equity | $m | [106](/filings/0001628280-26-018261.md) | [89.2](/filings/0001739410-25-000112.md) | [80.0](/filings/0001739410-25-000132.md) | [70.8](/filings/0001739410-25-000132.md) | [61.7](/filings/0001628280-26-067422.md) | [54.1](/filings/0001628280-26-053880.md) | [46.0](/filings/0001628280-26-067422.md) | [63.0](/filings/0001628280-26-067422.md) | [58.0](/filings/0001628280-26-067422.md) | [50.3](/filings/0001628280-26-053880.md) | [94.5](/filings/0001628280-26-067422.md) | [92.3](/filings/0001628280-26-067422.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.6) d](/filings/0001739410-25-000040.md) | [(15.5)](/filings/0001739410-25-000061.md) | [(10.4) d](/filings/0001739410-25-000112.md) | [(13.5) d](/filings/0001739410-25-000132.md) | [(9.9) d](/filings/0001628280-26-018261.md) | [(10.2)](/filings/0001628280-26-034580.md) | [(8.4) d](/filings/0001628280-26-053880.md) | [(6.6) d](/filings/0001628280-26-067422.md) | [(4.7) d](/filings/0001628280-26-018261.md) | [(8.0)](/filings/0001628280-26-034580.md) | [45.9 d](/filings/0001628280-26-053880.md) | [(2.3) d](/filings/0001628280-26-067422.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001739410-25-000040.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [40.2](/filings/0001739410-24-000057.md) | [40.4](/filings/0001739410-24-000115.md) | [40.5](/filings/0001739410-24-000136.md) | [40.8](/filings/0001739410-25-000061.md) | [44.1](/filings/0001739410-25-000112.md) | [44.6](/filings/0001739410-25-000132.md) | [5.6](/filings/0001628280-26-034580.md) | [44.8](/filings/0001739410-25-000112.md) | [5.6](/filings/0001628280-26-067422.md) | [5.7](/filings/0001628280-26-034580.md) | [5.8](/filings/0001628280-26-053880.md) | [5.7](/filings/0001628280-26-067422.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 5,383,937 at 2026-10-20, from the cover of the [10-Q filed 2026-10-27](/filings/0001628280-26-067422.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:38 ET. No prices; not investment advice.